These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28202674)

  • 21. Phosphorylation of LRRK2: from kinase to substrate.
    Lobbestael E; Baekelandt V; Taymans JM
    Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients.
    Dzamko N; Chua G; Ranola M; Rowe DB; Halliday GM
    J Parkinsons Dis; 2013; 3(2):145-52. PubMed ID: 23938344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients.
    Fernández B; Lara Ordóñez AJ; Fdez E; Mutez E; Comptdaer T; Leghay C; Kreisler A; Simonin C; Vandewynckel L; Defebvre L; Destée A; Bleuse S; Taymans JM; Chartier-Harlin MC; Hilfiker S
    Biochem J; 2019 Oct; 476(19):2797-2813. PubMed ID: 31527116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson's Disease Patients and Healthy Subjects with Parkinson's-Associated LRRK2 Mutations?
    Loeffler DA; Aasly JO; LeWitt PA; Coffey MP
    J Parkinsons Dis; 2019; 9(3):467-488. PubMed ID: 31322581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice.
    Zhao Y; Keshiya S; Atashrazm F; Gao J; Ittner LM; Alessi DR; Halliday GM; Fu Y; Dzamko N
    Neurobiol Dis; 2018 Dec; 120():76-87. PubMed ID: 30194047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.
    Mendivil-Perez M; Velez-Pardo C; Jimenez-Del-Rio M
    Neurochem Res; 2016 Oct; 41(10):2675-2692. PubMed ID: 27394417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease.
    Arora S; Visanji NP; Mestre TA; Tsanas A; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Lang AE; Little MA; Marras C
    J Parkinsons Dis; 2018; 8(4):503-510. PubMed ID: 30248062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.
    White LR; Toft M; Kvam SN; Farrer MJ; Aasly JO
    J Neurosci Res; 2007 May; 85(6):1288-94. PubMed ID: 17385669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First model of dimeric LRRK2: the challenge of unrevealing the structure of a multidomain Parkinson's-associated protein.
    Guaitoli G; Gilsbach BK; Raimondi F; Gloeckner CJ
    Biochem Soc Trans; 2016 Dec; 44(6):1635-1641. PubMed ID: 27913672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.
    Smith GA; Jansson J; Rocha EM; Osborn T; Hallett PJ; Isacson O
    Mol Neurobiol; 2016 Oct; 53(8):5161-77. PubMed ID: 26399642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LRRK2 Phosphorylation.
    Nichols RJ
    Adv Neurobiol; 2017; 14():51-70. PubMed ID: 28353278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The LRRK2 signalling system.
    Price A; Manzoni C; Cookson MR; Lewis PA
    Cell Tissue Res; 2018 Jul; 373(1):39-50. PubMed ID: 29308544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease.
    Fraser KB; Rawlins AB; Clark RG; Alcalay RN; Standaert DG; Liu N; ; West AB
    Mov Disord; 2016 Oct; 31(10):1543-1550. PubMed ID: 27297049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-variance RNAs identify Parkinson's disease molecular signature in blood.
    Chikina MD; Gerald CP; Li X; Ge Y; Pincas H; Nair VD; Wong AK; Krishnan A; Troyanskaya OG; Raymond D; Saunders-Pullman R; Bressman SB; Yue Z; Sealfon SC
    Mov Disord; 2015 May; 30(6):813-21. PubMed ID: 25786808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation.
    Madero-Pérez J; Fdez E; Fernández B; Lara Ordóñez AJ; Blanca Ramírez M; Gómez-Suaga P; Waschbüsch D; Lobbestael E; Baekelandt V; Nairn AC; Ruiz-Martínez J; Aiastui A; López de Munain A; Lis P; Comptdaer T; Taymans JM; Chartier-Harlin MC; Beilina A; Gonnelli A; Cookson MR; Greggio E; Hilfiker S
    Mol Neurodegener; 2018 Jan; 13(1):3. PubMed ID: 29357897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leucine-rich repeat kinase 2 and Parkinson's disease.
    Kang UB; Marto JA
    Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27723254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular functions of LRRK2 implicate vesicular trafficking pathways in Parkinson's disease.
    Cookson MR
    Biochem Soc Trans; 2016 Dec; 44(6):1603-1610. PubMed ID: 27913668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LRRK2 and Rab GTPases.
    Pfeffer SR
    Biochem Soc Trans; 2018 Dec; 46(6):1707-1712. PubMed ID: 30467121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LRRK2 in Parkinson's disease: protein domains and functional insights.
    Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
    Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LRRK2 in Infection: Friend or Foe?
    Herbst S; Gutierrez MG
    ACS Infect Dis; 2019 Jun; 5(6):809-815. PubMed ID: 30915830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.